Knockdown of circular RNA septin 9 inhibits the malignant progression of breast cancer by reducing the expression of solute carrier family 1 member 5 in a microRNA-149-5p-dependent manner

References

• DeSantis CE, Ma J, Goding Sauer A, et al. Breast cancer statistics, 2017, racial disparity in mortality by state. CA Cancer J Clin. 2017;67(6):439–448.
   PubMed Web of Science ®Google Scholar
• Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.
   PubMed Web of Science ®Google Scholar
• van Diest PJ, Van Der Wall E, Baak JP. Prognostic value of proliferation in invasive breast cancer: a review. J Clin Pathol. 2004;57(7):675–681.
   PubMed Web of Science ®Google Scholar
• Okholm TLH, Nielsen MM, Hamilton MP, et al. Circular RNA expression is abundant and correlated to aggressiveness in early-stage bladder cancer. NPJ Genom Med. 2017;2:36.
   PubMed Web of Science ®Google Scholar
• Kristensen LS, Andersen MS, Stagsted LVW, et al. The biogenesis, biology and characterization of circular RNAs. Nat Rev Genet. 2019;20(11):675–691.
   PubMed Web of Science ®Google Scholar
• Wang Y, Mo Y, Gong Z, et al. Circular RNAs in human cancer. Mol Cancer. 2017;16(1):25.
   PubMed Web of Science ®Google Scholar
• Liu Z, Zhou Y, Liang G, et al. Circular RNA hsa_circ_001783 regulates breast cancer progression via sponging miR-200c-3p. Cell Death Dis. 2019;10(2):55.
   PubMed Web of Science ®Google Scholar
• Zhang J, Ke S, Zheng W, et al. Hsa_circ_0003645 promotes breast cancer progression by regulating miR-139-3p/HMGB1 axis. Onco Targets Ther. 2020;13:10361–10372.
   PubMedGoogle Scholar
• Qiu X, Wang Q, Song H, et al. circ_103809 promotes breast cancer progression by regulating the PI3K/AKT signaling pathway. Oncol Lett. 2020;19(6):3725–3730.
   PubMed Web of Science ®Google Scholar
• Butler EB, Zhao Y, Muñoz-Pinedo C, et al. Stalling the engine of resistance: targeting cancer metabolism to overcome therapeutic resistance. Cancer Res. 2013;73(9):2709–2717.
   PubMed Web of Science ®Google Scholar
• Hensley CT, Wasti AT, DeBerardinis RJ. Glutamine and cancer: cell biology, physiology, and clinical opportunities. J Clin Invest. 2013;123(9):3678–3684.
   PubMed Web of Science ®Google Scholar
• Kaadige MR, Looper RE, Kamalanaadhan S, et al. Glutamine-dependent anapleurosis dictates glucose uptake and cell growth by regulating MondoA transcriptional activity. Proc Natl Acad Sci U S A. 2009;106(35):14878–14883.
   PubMed Web of Science ®Google Scholar
• Yuneva MO, Fan TW, Allen TD, et al. The metabolic profile of tumors depends on both the responsible genetic lesion and tissue type. Cell Metab. 2012;15(2):157–170.
   PubMed Web of Science ®Google Scholar
• Kanai Y, Hediger MA. The glutamate/neutral amino acid transporter family SLC1: molecular, physiological and pharmacological aspects. Pflugers Arch. 2004;447(5):469–479.
   PubMed Web of Science ®Google Scholar
• Huang F, Zhao Y, Zhao J, et al. Upregulated SLC1A5 promotes cell growth and survival in colorectal cancer. Int J Clin Exp Pathol. 2014;7(9):6006–6014.
   PubMed Web of Science ®Google Scholar
• van Geldermalsen M, Wang Q, Nagarajah R, et al. ASCT2/SLC1A5 controls glutamine uptake and tumour growth in triple-negative basal-like breast cancer. Oncogene. 2016;35(24):3201–3208.
   PubMed Web of Science ®Google Scholar
• Friedman RC, Farh KK, Burge CB, et al. Most mammalian mRNAs are conserved targets of microRNAs. Genome Res. 2009;19(1):92–105.
   PubMed Web of Science ®Google Scholar
• Chen J, Jiang Q, Jiang XQ, et al. miR-146a promoted breast cancer proliferation and invasion by regulating NM23-H1. J Biochem. 2020;167(1):41–48.
   PubMed Web of Science ®Google Scholar
• Ruan L, Qian X. MiR-16-5p inhibits breast cancer by reducing AKT3 to restrain NF-κB pathway. Biosci Rep. 2019;39(8):8.
   Google Scholar
• Hui C, Tian L, He X. Circular RNA circNHSL1 Contributes to Gastric Cancer Progression Through the miR-149-5p/YWHAZ Axis. Cancer Manag Res. 2020;12:7117–7130.
   PubMed Web of Science ®Google Scholar
• Meng X, Sun W, Yu J, et al. LINC00460-miR-149-5p/miR-150-5p-mutant p53 feedback loop promotes oxaliplatin resistance in colorectal cancer. Mol Ther Nucleic Acids. 2020;22:1004–1015.
   PubMedGoogle Scholar
• Xu M, Xiao J, Chen M, et al. miR‑149‑5p promotes chemotherapeutic resistance in ovarian cancer via the inactivation of the Hippo signaling pathway. Int J Oncol. 2018;52(3):815–827.
   PubMed Web of Science ®Google Scholar
• Sánchez-González I, Bobien A, Molnar C, et al. miR-149 suppresses breast cancer metastasis by blocking paracrine interactions with macrophages. Cancer Res. 2020;80(6):1330–1341.
   PubMed Web of Science ®Google Scholar
• Lu H, Li X, Lu Y, et al. ASCT2 (SLC1A5) is an EGFR-associated protein that can be co-targeted by cetuximab to sensitize cancer cells to ROS-induced apoptosis. Cancer Lett. 2016;381(1):23–30.
   PubMed Web of Science ®Google Scholar
• Wu Y, Xie Z, Chen J, et al. Circular RNA circTADA2A promotes osteosarcoma progression and metastasis by sponging miR-203a-3p and regulating CREB3 expression. Mol Cancer. 2019;18(1):73.
   PubMed Web of Science ®Google Scholar
• Pan G, Mao A, Liu J, et al. Circular RNA hsa_circ_0061825 (circ-TFF1) contributes to breast cancer progression through targeting miR-326/TFF1 signalling. Cell Prolif. 2020;53(2). e12720-e12720. doi:10.1111/cpr.12720.
   Web of Science ®Google Scholar
• Lu H, Li X, Luo Z, et al. Cetuximab reverses the Warburg effect by inhibiting HIF-1-regulated LDH-A. Mol Cancer Ther. 2013;12(10):2187–2199.
   PubMed Web of Science ®Google Scholar
• Qiu N, Xu X, He Y. LncRNA TUG1 alleviates sepsis-induced acute lung injury by targeting miR-34b-5p/GAB1. BMC Pulm Med. 2020;20(1):49.
   PubMed Web of Science ®Google Scholar
• Huang D-W, Huang M, Lin X-S, et al. CD155 expression and its correlation with clinicopathologic characteristics, angiogenesis, and prognosis in human cholangiocarcinoma. Onco Targets Ther. 2017;10:3817–3825.
   PubMed Web of Science ®Google Scholar
• Chen B, Wei W, Huang X, et al. circEPSTI1 as a prognostic marker and mediator of triple-negative breast cancer progression. Theranostics. 2018;8(14):4003–4015.
   PubMed Web of Science ®Google Scholar
• Kong Y, Yang L, Wei W, et al. CircPLK1 sponges miR-296-5p to facilitate triple-negative breast cancer progression. Epigenomics. 2019;11(10):1163–1176.
   PubMed Web of Science ®Google Scholar
• Tang H, Huang X, Wang J, et al. circKIF4A acts as a prognostic factor and mediator to regulate the progression of triple-negative breast cancer. Mol Cancer. 2019;18(1):23.
   PubMed Web of Science ®Google Scholar
• Liang G, Ling Y, Mehrpour M, et al. Autophagy-associated circRNA circCDYL augments autophagy and promotes breast cancer progression. Mol Cancer. 2020;19(1):65.
   PubMed Web of Science ®Google Scholar
• Song H, Sun J, Kong W, et al. Construction of a circRNA-related ceRNA prognostic regulatory network in breast cancer. Onco Targets Ther. 2020;13:8347–8358.
   PubMed Web of Science ®Google Scholar
• Yue L, Wang G, Zhu M. CircRNA SEPT9 contributes to malignant behaviors of glioma cells via miR-432-5p-mediated regulation of LASP1. Brain Res. 2021;1766:147501.
   PubMed Web of Science ®Google Scholar
• Ju H, Zhang L, Mao L, et al. Altered expression pattern of circular RNAs in metastatic oral mucosal melanoma. Am J Cancer Res. 2018;8(9):1788–1800.
   PubMed Web of Science ®Google Scholar
• Zheng X, Huang M, Xing L, et al. The circRNA circSEPT9 mediated by E2F1 and EIF4A3 facilitates the carcinogenesis and development of triple-negative breast cancer. Mol Cancer. 2020;19(1):73.
   PubMed Web of Science ®Google Scholar
• Hou H, Luo C, Chen Z, et al. [Correlation of glutamate dehydrogenase with several tumors]. Sheng Wu Gong Cheng Xue Bao. 2019;35(3):389–395.
   PubMedGoogle Scholar
• Craze ML, El-Ansari R, Aleskandarany MA, et al. Glutamate dehydrogenase (GLUD1) expression in breast cancer. Breast Cancer Res Treat. 2019;174(1):79–91.
   PubMed Web of Science ®Google Scholar
• Alfarsi LH, El Ansari R, Craze ML, et al. SLC1A5 co-expression with TALDO1 associates with endocrine therapy failure in estrogen receptor-positive breast cancer. Breast Cancer Res Treat. 2021;189(2):317–331.
   PubMed Web of Science ®Google Scholar
• Kong YG, Cui M, Chen SM, et al. LncRNA-LINC00460 facilitates nasopharyngeal carcinoma tumorigenesis through sponging miR-149-5p to up-regulate IL6. Gene. 2018;639:77–84.
   PubMed Web of Science ®Google Scholar
• Ye X, Chen X. miR-149-5p inhibits cell proliferation and invasion through targeting GIT1 in medullary thyroid carcinoma. Oncol Lett. 2019;17(1):372–378.
   PubMed Web of Science ®Google Scholar
• Qi C, Qin X, Zhou Z, et al. Circ_0072995 promotes cell carcinogenesis via up-regulating miR-149-5p-mediated SHMT2 in breast cancer. Cancer Manag Res. 2020;12:11169–11181.
   PubMed Web of Science ®Google Scholar
• Tian D, Tian M, Ma ZM, et al. Anesthetic propofol epigenetically regulates breast cancer trastuzumab resistance through IL-6/miR-149-5p axis. Sci Rep. 2020;10(1):8858.
   PubMed Web of Science ®Google Scholar